Fmr LLC Purchases 3,635 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB)

Fmr LLC grew its position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) by 29.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,855 shares of the biopharmaceutical company’s stock after purchasing an additional 3,635 shares during the quarter. Fmr LLC owned approximately 0.25% of Assembly Biosciences worth $240,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Acadian Asset Management LLC boosted its stake in Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 7,690 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Assembly Biosciences in the 2nd quarter worth approximately $6,421,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Assembly Biosciences news, major shareholder Alexander Schornstein purchased 10,000 shares of the stock in a transaction on Tuesday, October 8th. The stock was acquired at an average price of $14.58 per share, with a total value of $145,800.00. Following the transaction, the insider now directly owns 703,113 shares of the company’s stock, valued at approximately $10,251,387.54. This trade represents a 1.44 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 394 shares of company stock valued at $5,894 in the last quarter. Insiders own 5.10% of the company’s stock.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $15.21 on Friday. Assembly Biosciences, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $19.93. The business has a 50 day moving average price of $16.35 and a 200-day moving average price of $15.59.

Analyst Ratings Changes

A number of equities analysts recently commented on ASMB shares. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Tuesday, September 24th. Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $2.00 to $35.00 in a research note on Friday, September 20th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.